Effects of tobacco smoke and electronic cigarette vapor exposure on the oral and gut microbiota in humans:
a pilot study

Christopher J. Stewart1,2, Thomas A. Auchtung1, Nadim J. Ajami1, Kenia Velasquez3,4, Daniel P. Smith1, Richard De La Garza II3,4,5, Ramiro Salas3,4,5 and Joseph F. Petrosino1

1 Alkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA
2 Institute of Cellular Medicine, Newcastle University, Newcastle, UK
3 Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA
4 Veteran Affairs Medical Center, Michael E. DeBakey VA Medical Center, Houston, TX, USA
5 Department of Neuroscience, Baylor College of Medicine, Houston, TX, USA

ABSTRACT

Background: The use of electronic cigarettes (ECs) has increased drastically over the past five years, primarily as an alternative to smoking tobacco cigarettes. However, the adverse effects of acute and long-term use of ECs on the microbiota have not been explored. In this pilot study, we sought to determine if ECs or tobacco smoking are associated with differences in the oral and gut microbiota, in comparison to non-smoking controls.

Methods: We examined a human cohort consisting of 30 individuals: 10 EC users, 10 tobacco smokers, and 10 controls. We collected cross-sectional fecal, buccal swabs, and saliva samples from each participant. All samples underwent V4 16S rRNA gene sequencing.

Results: Tobacco smokers had significantly different bacterial profiles in all sample types when compared to controls, and in feces and buccal swabs when compared to EC users. The most significant associations were found in the gut, with a higher relative abundance of Prevotella (P = 0.006) and lowered Bacteroides (P = 0.036) in tobacco smokers. The Shannon diversity was also significantly reduced (P = 0.009) in fecal samples collected from tobacco smokers compared to controls. No significant difference was found in the alpha diversity, beta-diversity or taxonomic relative abundances between EC users and controls.

Discussion: The current pilot data demonstrate that tobacco smoking is associated with significant differences in the oral and gut microbiome in humans. However, validation in larger cohorts and greater understanding of the short and long-term impact of EC use on microbiota composition and function is warranted.

Subjects  Microbiology, Molecular Biology
Keywords  Smoking, Microbiota, Electronic cigarette, Tobacco
INTRODUCTION
Tobacco cigarettes are the leading cause of preventable diseases in the world (Cahn & Siegel, 2011). Smoking increases the risk for development of several diseases, including cardiovascular disease (Lubin et al., 2016), various cancers (Jacobs et al., 2015), especially lung cancer (Montserrat-Capdevila et al., 2016), and inflammatory bowel disease (Higuchi et al., 2012). Electronic cigarettes (ECs) offer promise as a tool to quit or an alternative to tobacco smoking. It is estimated that over 12% of adults in the US have used ECs (Kosmider et al., 2016). Use of ECs is tripling annually with consumers including non-tobacco smoking adolescents and adults (Moon, Lee & Lee, 2015; Bostean, Trinidad & McCarthy, 2015). While ECs primarily contain propylene glycol, vegetable glycerin, and nicotine, tobacco cigarettes are composed of over 4,000 other chemicals and particulate matter (You et al., 2015). Studies reporting negative health effects relating to ECs are scarce and ECs remain unregulated, but commercial ECs have been reported to contain low levels of toxic compounds (Cahn & Siegel, 2011; Varlet et al., 2015; Kosmider et al., 2016; Allen et al., 2016).

There are relatively few studies exploring the effects of tobacco smoke on the microbiota and we are not aware of any study to date that has compared the bacterial communities in tobacco smokers and EC users. In one human study, the oral microbiota was different between healthy non-smokers and tobacco smokers, with lower Porphyromonas, Neisseria, and Gemella in tobacco smokers, but the lung communities were not affected (Morris et al., 2013). Smoking has also been shown to drive changes in the sputum microbiota more than other lifestyle factors (e.g., exercise and alcohol), increasing the relative abundance of Veillonella and Megasphaera (Lim et al., 2016). A recent large-scale sequencing study of the oral microbiota in current, previous, or non-smokers demonstrated current smokers had distinct oral communities, with lower relative abundance of Proteobacteria (Wu et al., 2016). Notably, the significant taxa vary between studies and a recent analysis of numerous sites within the mouth found no significant difference between smokers and controls in any site, with the exception of the buccal mucosa (Yu et al., 2017). Quitting smoking has been shown to increase bacterial diversity and alter community composition in both the mouth (Delima et al., 2010) and gut (Biedermann et al., 2013). Besides human cohort research, the gut microbiota has been shown to differ in tobacco smoke exposed mice, in comparison to air-only exposure (Wang, 2012; Allais et al., 2016).

The current study represents the first exploration of EC vapor and tobacco smoke exposure on the oral (buccal and saliva) and gut bacterial communities.

MATERIALS AND METHODS
Study design and cohort
The study was approved by the Baylor College of Medicine Institutional Review Board (IRB H-38043). Written informed consent was obtained prior to collection of data and samples.
The cohort consisted of 30 individuals in three distinct exposure groups; EC users \((n = 10)\), tobacco smokers \((n = 10)\), and matched controls \((n = 10)\). All participants were recruited from the Houston area. Inclusion criteria for EC users included daily use of ECs for at least six months. Inclusion criteria for tobacco smokers included an Fagerstrom test for nicotine dependence and smoked a minimum of 10 cigarettes per day. Subject variables between the three exposure groups were comparable, with no significant difference in the sex, age, diet, height/weight, or race (Table 1). Notably, only 2/30 samples were from female participants. One EC user (EC7) reported occasionally smoking one tobacco cigarette per week and no other EC users reported use of tobacco cigarettes. EC7 had a comparable carbon monoxide (CO) ppm to other EC users and controls. No tobacco smokers reported use of EC. EC users vaped regularly throughout the day, used ECs daily, and had been actively using ECs for a median of three years.

### DNA extraction

DNA was extracted from 125 mg of fresh fecal samples using the AllPrep Bacterial kit (Mo Bio 47054; Mo Bio Laboratories, Carlsbad, CA, USA) as per the manufacturers’ protocol. Entire buccal swabs and 500 μl saliva samples were extracted using the

---

**Table 1** Subject information for the human cohort per exposure group.

<table>
<thead>
<tr>
<th></th>
<th>Controls</th>
<th>Electronic cigarette</th>
<th>Tobacco smoke</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex</td>
<td>90%</td>
<td>90%</td>
<td>100%</td>
</tr>
<tr>
<td>Age in years, median (IQR)</td>
<td>31 (28–36)</td>
<td>29 (24–37)</td>
<td>35 (30–45)</td>
</tr>
<tr>
<td>Diet</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meat eater</td>
<td>90%</td>
<td>90%</td>
<td>100%</td>
</tr>
<tr>
<td>Vegetarian</td>
<td>10%</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Vegan</td>
<td>0</td>
<td>10%</td>
<td>0</td>
</tr>
<tr>
<td>Body mass index, median (IQR)</td>
<td>23.5 (22.5–24.5)</td>
<td>24.5 (22.5–26.7)</td>
<td>24 (21.5–25.5)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>60%</td>
<td>70%</td>
<td>60%</td>
</tr>
<tr>
<td>Hispanic</td>
<td>10%</td>
<td>20%</td>
<td>10%</td>
</tr>
<tr>
<td>Asian</td>
<td>30%</td>
<td>10%</td>
<td>0</td>
</tr>
<tr>
<td>Black</td>
<td>0</td>
<td>0</td>
<td>30%</td>
</tr>
<tr>
<td>Electronic cigarette</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicotine concentration (mg), median (IQR)</td>
<td>–</td>
<td>9 (6–12)</td>
<td>–</td>
</tr>
<tr>
<td>Volume (ml)/day, median (IQR)</td>
<td>–</td>
<td>8 (3–19)</td>
<td>–</td>
</tr>
<tr>
<td>Years using, median (IQR)</td>
<td>–</td>
<td>3 (2–4)</td>
<td>–</td>
</tr>
<tr>
<td>Tobacco smoke</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cigarettes/day, median (IQR)</td>
<td>0</td>
<td>0.2 (0.2–0.2)</td>
<td>14 (10–19)</td>
</tr>
<tr>
<td>FTND, median (IQR)</td>
<td>0</td>
<td>0</td>
<td>5 (4–6)</td>
</tr>
<tr>
<td>Carbon monoxide (ppm), median (IQR)</td>
<td>1 (1–2)</td>
<td>3 (3–4)</td>
<td>19 (14–24)</td>
</tr>
</tbody>
</table>

**Note:**

IQR, interquartile range; FTND, Fagerstrom test for nicotine dependence.
PowerMicrobiome RNA isolation kit (Mo Bio 26000-50; Mo Bio Laboratories, Carlsbad, CA, USA) as per the manufacturers’ protocol, omitting the necessary steps for co-elution of DNA and RNA, and with elution of nucleic acids in 50 µl.

**16S rRNA gene sequencing**

The bacterial 16S rRNA gene V4 region was amplified by PCR using barcoded Illumina adapter-containing primers 515F and 806R (Caporaso et al., 2012) and sequenced with the 2 × 250 bp cartridges in the MiSeq platform (Illumina, San Diego, USA). The read pairs were demultiplexed and reads were merged using USEARCH v7.0.1090 (Edgar, 2010). Merging allowed zero mismatches and a minimum overlap of 50 bases, and merged reads were trimmed at the first base with a Q ≤ 5. A quality filter was applied to the resulting merged reads and those containing above 0.5% expected errors were discarded. Sequences were stepwise clustered into operational taxonomic units (OTUs) at a similarity cutoff value of 97% using the UPARSE algorithm (Edgar, 2013). Chimeras were removed using USEARCH v7.0.1090 and UCHIME. To determine taxonomies, OTUs were mapped to a version of the SILVA database (Quast et al., 2013) containing only the 16S V4 region using USEARCH v7.0.1090. Abundances were recovered by mapping the merged reads to the UPARSE OTUs. A rarefied OTU table was constructed from the output files generated in the previous two steps for downstream analyses of alpha diversity, beta diversity (including UniFrac), and phylogenetic trends (Lozupone & Knight, 2005).

**Statistical analysis**

Samples were rarefied to 4,000 reads and rarefaction resulted in the loss of all negative controls for each DNA extraction kit. Analysis and visualization of bacterial communities was conducted in R (R Development Core Team, 2014). For analysis of alpha diversity and taxonomic relative abundance, the Kruskal–Wallis test (Kruskal & Wallis, 1952) was first applied to determine the overall statistical significance of the three groups. Only if the Kruskal–Wallis test showed a P < 0.05, pairwise significance was determined based on the Mann–Whitney test (Mann & Whitney, 1947). Differences in beta diversity (weighted Unifrac distance) were assessed using PERMANOVA. Linear regression was performed in R using the lm() function. When comparing more than one measure, such as multiple measures of alpha diversity or for multiple taxonomic genera, P-values were adjusted for multiple comparisons with the false discovery rate (FDR) algorithm (Benjamini & Hochberg, 1995).

All data and metadata files, as well as the R code used in the analysis, are provided in the Supplemental Information.

**RESULTS**

**Microbiota specific to sample site**

Feces had a distinct bacterial profile compared to the oral samples (buccal swab and saliva) (Fig. S1A). The Shannon diversity indices were higher in saliva (P < 0.001) and feces (P < 0.001) in comparison to buccal swab samples (Fig. S1B). Dominant bacterial genera were also significantly different (P < 0.001) between the three
sample types (Fig. S1C). Thus, analyses exploring tobacco smoking or EC use were stratified by sample type.

**Alpha diversity of feces is lower in tobacco smokers**
The Shannon diversity was significantly lower in fecal samples collected from tobacco smokers compared to controls ($P = 0.009$), but the number of observed OTUs was comparable between all groups (Fig. 1A). No significant difference was found in the number of OTUs or Shannon diversity between the groups in buccal swabs and saliva samples (Figs. 1B and 1C).

**Bacterial profiles of feces and oral sites are significantly different in tobacco smokers**
Weighted UniFrac PCoA, a quantitative distance metric incorporating phylogenetic distances between taxa, showed tobacco smokers had significantly different fecal bacterial profiles compared to controls ($P = 0.027$) and EC users ($P = 0.009$), but controls and EC users were not significantly different ($P = 0.261$) (Fig. 2A). This was consistent in buccal swabs, where bacterial profiles were significantly different between tobacco smokers compared to controls ($P = 0.049$) and EC users ($P = 0.033$), but controls and EC users were comparable ($P = 0.886$) (Fig. 2B). In saliva samples, the microbiota profiles of tobacco smokers and controls were significantly different ($P = 0.046$) and EC users were comparable to both tobacco smokers and controls (Fig. 2C).

**The relative abundance of bacterial genera was significantly associated with tobacco smoking in feces only**
Fecal samples had a total of two genera significantly different between the three groups, with higher *Prevotella* ($P = 0.006$) and lower *Bacteroides* ($P = 0.036$) in tobacco smokers (Fig. 3). Further pairwise comparisons of these genera showed *Prevotella* had significantly higher relative abundance in tobacco smokers compared to controls ($P = 0.008$) and EC users ($P = 0.003$), but no difference between EC users and controls ($P = 0.99$). Whereas *Bacteroides* showed significantly lower relative abundance in tobacco smokers compared to controls ($P = 0.017$) and EC users ($P = 0.003$), but no difference between EC users and controls ($P = 0.684$). No significant difference in any bacterial genera was observed between the different groups in saliva or buccal swab samples (Fig. S2). These findings were also supported by correlations with CO levels, which reflect the amount an individual smoked tobacco cigarettes. Specifically, no genus was significantly associated with saliva or buccal swab samples, but *Bacteroides* was negatively correlated with CO level ($P = 0.042$) and *Prevotella* was positively correlated with CO levels ($P = 0.011$) (Table S1; Fig. S3).

**DISCUSSION**
This pilot study aimed to characterize EC vapor and tobacco smoke exposure on the bacterial profiles at multiple distinct and relevant body sites in a human cohort. To our knowledge this work represents the first study to concurrently explore the associations of EC vapor and tobacco smoke exposure on the microbiota. With users of ECs increasing at...
Figure 1  Boxplots of bacterial alpha diversity. Analysis stratified per sample type. Controls (Con; orange); electronic cigarette (EC; blue); tobacco smoke (TS; green). Significance based on non-parametric Mann–Whitney test with FDR adjustment for multiple comparisons. Number of operational taxonomic units (OTUs) (A) and Shannon diversity (B) in feces. Number of OTUs (C) and Shannon diversity (D) in buccal swabs. Number of OTUs (E) and Shannon diversity (F) in saliva.

Stewart et al. (2018), PeerJ, DOI 10.7717/peerj.4693/fig-1
Figure 2  Weighted UniFrac principal coordinate analysis (PCoA). Analysis stratified per sample type. Controls (Con; orange); electronic cigarette (EC; blue); tobacco smoke (TS; green). Significance based on PERMANOVA. (A) Feces. (B) Buccal swab. (C) Saliva.

Full-size DOI: 10.7717/peerj.4693/fig-2
an unprecedented rate, it is imperative to understand the potential influences on host
well-being, for which the oral and gut microbiota may have important consequences.

We report, for the first time, that people who regularly use ECs do not have measurably
different oral or gut bacterial communities compared to non-smoking controls. However,
compared to non-smoking controls, tobacco smokers had significantly different bacterial
profiles in all samples analyzed, with the most significant associations found in the gut.
This is in accordance with existing data showing the gut microbiota changes following
smoking cessation (Biedermann et al., 2013, 2014). This is reflected in the alpha diversity
analyses, where the fecal microbiota of tobacco smokers had significantly lower Shannon
diversity compared to controls. Previous studies have also showed the Shannon diversity
is lower in tobacco smokers compared to matched non-smokers in the gut (Opstelten
et al., 2016), but recovers upon smoking cessation (Biedermann et al., 2013). Although
smoking was recently reported to reduce buccal diversity (Yu et al., 2017), we found no
difference in the diversity between the groups in buccal swabs. Overall, such studies
provide further evidence for a direct effect of tobacco smoke in restricting microbial
diversity and/or providing favorable conditions for specific taxa. The low bacterial
diversity in the gut was striking, which may have important consequences for health and
the risk of certain diseases. While inconclusive, low bacterial diversity has been associated
with a range of conditions, including inflammatory bowel disease (Ott & Schreiber, 2006;
Durban et al., 2012; Sha et al., 2013), obesity (Turnbaugh et al., 2009), colorectal cancer
(Ahn et al., 2013), and asthma (Abrahamsson et al., 2014).
Only the fecal microbiota was found to have specific genera significantly different between exposure groups, with higher relative abundance of *Prevotella*, in accordance with existing data (Benjamin et al., 2012). Conversely, smoking tobacco cigarettes was associated with significantly lower relative abundance of *Bacteroides* compared to EC users and controls. *Prevotella* and *Bacteroides* are dominant members of the human gut microbiome (Arunugam et al., 2011; Koren et al., 2013; Gorvitovskaia, Holmes & Huse, 2016). *Prevotella* is associated with a high fiber diet and living in rural conditions (De Filippo et al., 2010; Ou et al., 2013; Tyakht et al., 2013; Kovatcheva-Datchary et al., 2015), whereas high *Bacteroides* abundance in the gut is generally attributed to a protein, fat, and sugar rich diet and a Western lifestyle (De Filippo et al., 2010; Ou et al., 2013). *Prevotella* and *Bacteroides* may have important implications for health and disease, with several species of the *Bacteroides* genus considered beneficial or probiotic (Xu & Gordon, 2003; Backhed et al., 2005) though some are considered opportunistic human pathogens. Existing evidence suggests intestinal inflammation, such as in Crohn's disease, is associated with reduced abundance of *Bacteroides* (Guinane & Cotter, 2013). Furthermore, a reduced *Bacteroides* abundance has been associated with obesity in both humans (Ley et al., 2006) and mice (Ley et al., 2005; Turnbaugh et al., 2006) studies, but the direct role of the microbiome in obesity causality remains an area of active discussion (Sze & Schloss, 2016). Conversely, high *Prevotella* in the gut has been associated with human colon cancer (Chen et al., 2012; Sivaprakasam et al., 2016) and susceptibility to colitis (Elinav et al., 2011; Chow, Tang & Mazmanian, 2011).

No taxa were significantly different in the oral (both buccal swab and saliva) microbiota. These results were surprising given the immediate proximity of the oral environment, relative to the gut, in smoke/vapor exposure. Indeed, smoking tobacco cigarettes has previously been shown to significantly alter the bacterial community in oral and lung samples (Charlson et al., 2010; Kozlowska et al., 2013; Mason et al., 2014; Wu et al., 2016). Conversely, existing studies have also reported no changes in smokers (Morris et al., 2013) and the taxa driving the separation vary between studies, which may reflect the differences in cohorts or methods, such as in specific site of sample collection, extraction, sequencing, and bioinformatics (Yu et al., 2017). Thus, further research in large multi-location cohorts is necessary to ascertain the direct effects of smoking across respiratory sites. Notably, both *Prevotella* and *Bacteroides* were highly specific to fecal samples (Table S2; Fig. S3), further demonstrating the precise effects of tobacco smoke exposure on taxa exogenous to the gut.

This study has several potential limitations. First, the cohort information was collected by questionnaire and while one EC user reported occasional use of tobacco cigarettes (one per week maximum), it is possible other participants used tobacco cigarettes and did not report this. However, to control for this we tested the CO levels (reflective of smoke inhalation) in all individuals and found tobacco smokers had higher CO ppm compared to EC users and controls, which would be expected (Table 1). Second, it is possible that the study was underpowered to detect subtle changes in the different sample sites and within some of the patient demographics. Third, only 2/30 participants in the study were female and, given the potential for sex-specific microbiota profiles (Haro et al., 2016),
additional work is needed to determine if the findings differ between males and females. Further longitudinal work with frequent sampling in larger human cohorts is needed to validate the associations reported in this study and determine the potential mechanism and impact on host health. Despite an absence of taxonomic change in EC vapor exposure, determining potential changes to microbial and host functioning also represents an important area for subsequent research.

CONCLUSION

In summary, we found that tobacco smoking was associated with significant differences in the bacterial profiles in feces, buccal, and saliva samples. Compared to controls, exposure to ECs made no difference to the oral or gut microbial communities. Differences in the gut communities of tobacco smokers were associated with higher relative abundance of Prevotella and lower relative abundance of Bacteroides. Other end points besides the microbiota will be important to consider when determining the impact of ECs on human health and disease. At a time when EC use continues to rise, we highlight the need for greater understanding on the direct short and long-term impact of exposure to vapor on the microbiome composition and function.

ACKNOWLEDGEMENTS

We also wish to thank the participants involved in this work.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This work was supported by NCI (3P30CA0125123-09S1); the Veteran Health Administration (VHA5I01CX000994); and the McNair Medical Institute. This material is partly the result of work supported with resources and the use of facilities at the Michael E. DeBakey VA Medical Center, Houston, TX. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:
NCI: 3P30CA0125123-09S1.
Veteran Health Administration: VHA5I01CX000994.
McNair Medical Institute.

Competing Interests

The authors declare that they have no competing interests.

Author Contributions

- Christopher J. Stewart conceived and designed the experiments, performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
Thomas A. Auchtung performed the experiments, authored or reviewed drafts of the paper, approved the final draft.

Nadim J. Ajami performed the experiments, authored or reviewed drafts of the paper, approved the final draft.

Kenia Velasquez performed the experiments, authored or reviewed drafts of the paper, approved the final draft.

Daniel P. Smith analyzed the data, authored or reviewed drafts of the paper, approved the final draft.

Richard De La Garza II conceived and designed the experiments, contributed reagents/materials/analysis tools, authored or reviewed drafts of the paper, approved the final draft.

Ramiro Salas conceived and designed the experiments, contributed reagents/materials/analysis tools, authored or reviewed drafts of the paper, approved the final draft.

Joseph F. Petrosino conceived and designed the experiments, contributed reagents/materials/analysis tools, authored or reviewed drafts of the paper, approved the final draft.

Human Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The study was approved by the Baylor College of Medicine Institutional Review Board.

Data Availability
The following information was supplied regarding data availability:

The sequencing data generated in this study are available in the European Nucleotide Archive under project accession number PRJNA413706.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.4693#supplemental-information.

REFERENCES


Ott SJ, Schreiber S. 2006. Reduced microbial diversity in inflammatory bowel diseases. 


